These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 12647013)

  • 1. Population pharmacokinetics of oxaliplatin.
    Delord JP; Umlil A; Guimbaud R; Grégoire N; Lafont T; Canal P; Bugat R; Chatelut E
    Cancer Chemother Pharmacol; 2003 Feb; 51(2):127-31. PubMed ID: 12647013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer.
    Kho Y; Jansman FG; Prins NH; Neef C; Brouwers JR
    Ther Drug Monit; 2006 Apr; 28(2):206-11. PubMed ID: 16628132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.
    Baur M; Drescher A; Gneist M; Dittrich C; Jaehde U
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):97-104. PubMed ID: 17396265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of oxaliplatin: a critical review.
    Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
    Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin.
    Joel SP; Papamichael D; Richards F; Davis T; Aslanis V; Chatelut E; Locke K; Slevin ML; Seymour MT
    Clin Pharmacol Ther; 2004 Jul; 76(1):45-54. PubMed ID: 15229463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
    Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
    Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin pharmacokinetics during a four-hour infusion.
    Kern W; Braess J; Böttger B; Kaufmann CC; Hiddemann W; Schleyer E
    Clin Cancer Res; 1999 Apr; 5(4):761-5. PubMed ID: 10213210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of heated intraperitoneal oxaliplatin.
    Ferron G; Dattez S; Gladieff L; Delord JP; Pierre S; Lafont T; Lochon I; Chatelut E
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):679-83. PubMed ID: 18084764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
    Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
    Shirao K; Matsumura Y; Yamada Y; Muro K; Gotoh M; Boku N; Ohtsu A; Nagashima F; Sano Y; Mutoh M; Tanigawara Y
    Jpn J Clin Oncol; 2006 May; 36(5):295-300. PubMed ID: 16702162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of oxaliplatin in patients with metastatic cancer.
    Bastian G; Barrail A; Urien S
    Anticancer Drugs; 2003 Nov; 14(10):817-24. PubMed ID: 14597876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility.
    Guthoff I; Lotspeich E; Fester C; Wallin I; Schatz M; Ehrsson H; Kornmann M
    Anticancer Res; 2003; 23(6D):5203-8. PubMed ID: 14981990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery.
    Pérez-Ruixo C; Valenzuela B; Peris JE; Bretcha-Boix P; Escudero-Ortiz V; Farré-Alegre J; Pérez-Ruixo JJ
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):693-704. PubMed ID: 23274396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
    Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
    Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.
    Mougenot P; Pinguet F; Fabbro M; Culine S; Poujol S; Astre C; Bressolle F
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):503-12. PubMed ID: 15007638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis.
    Watayo Y; Kuramochi H; Hayashi K; Nakajima G; Kamikozuru H; Yamamoto M
    Jpn J Clin Oncol; 2010 Apr; 40(4):360-4. PubMed ID: 20085906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.